nCounter® Neuropathology Panel
Helping Your Research
Biomarker discovery and signature development are essential for identification of novel therapies and for earlier detection and development of therapies for neurodegenerative disorders like Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). The nCounter Neuropathology Panel helps perform comprehensive multiplex gene expression analysis in human or mouse samples with genes involved in six fundamental themes of neurodegeneration: neurotransmission, neuron-glia interaction, neuroplasticity, cell structure integrity, neuroinflammation, and metabolism.
- Developed for research of Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Huntington’s Disease, and other neurological disorders
- Includes unique cell typing feature for measuring the abundance of five important CNS cell types, including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells
How It Works
nCounter Neuropathology Panels utilize NanoString’s unique barcoding technology and the nCounter Analysis System to help accelerate your research.
Screen 770 genes specific for neurodegeneration
Comprehensively Assess 23 pathways
Monitor progression of neurodegeneration
Screen potential therapeutics
Discover biomarkers and develop signatures associated with neurodegeneration
Customize with up to 55 additional user-defined genes with the Panel Plus option
Get data quickly with a streamlined, user-friendly, and efficient workflow with only 15 minutes hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Genes included in the Neuropathology Panels provide unique cell profiling data for measuring the abundance1 of five important cell types including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells. The table below summarizes each cell type represented in the panels along with the gene content qualified through current literature references.
1Danaher P. et al. Gene expression markers of Tumor Infiltrating Leukocytes JITC 2017
Functional annotations for 23 fundamental pathways and processes were assigned across all genes in the Neuropathology Panels allowing for a practical view of important aspects of the onset and progression of neurodegenerative disease.
The bidirectional lung brain-axis of amyloid-β pathology: ozone dysregulates the peri-plaque microenvironment.
The mechanisms underlying how urban air pollution affects Alzheimer’s disease (AD) are largely unknown. Ozone (O3) is a reactive gas component of air pollution linked to increased AD risk, but is confined to the respiratory tract after inhalation, implicating the peripheral immune response to air pollution in AD neuropathology.
Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain.
A main impediment to effective development of new therapeutics for central nervous system disorders, and for the in vivo testing of biological hypotheses in the brain, is the ability to rapidly measure the effect of novel agents and treatment combinations on the pathophysiology of native brain tissue. We have developed a miniaturized implantable microdevice (IMD) platform, optimized for direct stereotactic insertion into the brain, which enables the simultaneous measurement of multiple drug effects on the native brain tissue in situ.
Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling.
Clinical symptoms correlate with underlying neurodegenerative changes in the vast majority of people. However, an intriguing group of individuals demonstrate neuropathologic changes consistent with Alzheimer disease (AD) yet remain cognitively normal (termed “resilient”).